HAART-mediated Cardiovascular Toxcity in HIV-1 Transgenic Rats: Mg Protection

HIV-1 转基因大鼠中 HAART 介导的心血管毒性:镁保护

基本信息

  • 批准号:
    8790053
  • 负责人:
  • 金额:
    $ 23.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-08-06 至 2016-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Abstract: Ritonavir-boosted atazanavir (ATV/RTV) + Truvada [tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)] combination is currently recommended as one of the first line HAART therapy for the antiretroviral-naive patients. This regimen, while being effective to suppress HIV-1 replication, may prove to have hyperlipidemia/endothelial oxidative stress, renal toxicity and injurious cardiac effects when chronically used in HIV-1 patients. We recently demonstrate that AZT alone or RTV alone can cause enhanced cardiac inflammation and dysfunction in rats; RTV further caused hyperlipidemia and eNOS down-regulation. Importantly, we have demonstrated that dietary Mg-supplementation alone diminished most of the AZT- or RTV-side effects. Since HIV-1 protein expression may separately lead to significant systemic and cardiovascular inflammation, we hypothesize that HAART-mediated chronic cardiovascular side effects are enhanced further during HIV-1 infection, and Mg-supplementation may be protective. To pursue these hypotheses, we propose to use an established HIV-1 transgenic rat model and the parent Fischer 344 rats for the following specific Aims: 1) Determine if HAART combination treatment further promotes systemic oxidative/nitrosative stress, hyperlipidemia and cardiac pathology and dysfunction in HIV-1 Transgenic Rats compared with HAART treatment in control rats. 2) Determine if Mg-supplementation attenuates HAART-mediated systemic inflammation, pathology, and cardiac dysfunction in HIV-1 Tg and control rats. Oxidative/nitrosative, lipid metabolic and pathological indices will be quantified by biochemical and immunohistochemical techniques; HAART/HIV-1 induced eNOS down-regulation and Mg effects will be assessed by qRT-PCR and western blot and by NO metabolites. Cardiac function will be determined in situ by echocardiography. The projected results may have a major impact on choosing Mg- supplementation as an effective and safe co-therapy against chronic cardiovascular toxicity induced by most current HAART regimens in HIV patients.
描述(由申请人提供):摘要:利托那韦增强的阿扎那韦(ATV/RTV)+ Truvada [富马酸替诺福韦酯/恩曲他滨(TDF/FTC)]组合目前被推荐为抗逆转录病毒初治患者的一线HAART治疗之一。该方案虽然有效抑制HIV-1复制,但当长期用于HIV-1患者时,可能证明具有高脂血症/内皮氧化应激、肾毒性和损伤心脏效应。我们最近证明,AZT单独或RTV单独可以引起大鼠心脏炎症和功能障碍增强; RTV进一步引起高脂血症和eNOS下调。重要的是,我们已经证明,膳食镁补充剂单独减少了大多数AZT或RTV的副作用。由于HIV-1蛋白表达可能分别导致显著的全身和心血管炎症,我们假设HAART介导的慢性心血管副作用在HIV-1感染期间进一步增强,镁补充剂可能具有保护作用。为了实现这些假设,我们建议使用已建立的HIV-1转基因大鼠模型和亲本Fischer 344大鼠用于以下特定目的:1)确定与对照大鼠中的HAART治疗相比,HAART组合治疗是否进一步促进HIV-1转基因大鼠中的全身性氧化/亚硝化应激、高脂血症和心脏病理和功能障碍。2)确定镁补充是否减弱HAART介导的全身炎症,病理学和心功能不全的HIV-1 Tg和对照大鼠。将通过生物化学和免疫组织化学技术定量氧化/亚硝化、脂质代谢和病理学指标;将通过qRT-PCR和蛋白质印迹以及NO代谢物评估HAART/HIV-1诱导的eNOS下调和Mg效应。将通过超声心动图原位确定心脏功能。预测的结果可能对选择镁补充剂作为有效和安全的联合疗法对抗HIV患者中大多数当前HAART方案诱导的慢性心血管毒性产生重大影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ivan Tong Mak其他文献

Ivan Tong Mak的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ivan Tong Mak', 18)}}的其他基金

HAART-mediated Cardiovascular Toxcity in HIV-1 Transgenic Rats: Mg Protection
HIV-1 转基因大鼠中 HAART 介导的心血管毒性:镁保护
  • 批准号:
    8906935
  • 财政年份:
    2014
  • 资助金额:
    $ 23.78万
  • 项目类别:
Cardioprotective Efficacy ofMg-Supplementation during HAART Therapy
HAART 治疗期间补充镁的心脏保护作用
  • 批准号:
    8147831
  • 财政年份:
    2010
  • 资助金额:
    $ 23.78万
  • 项目类别:
Cardioprotective Efficacy ofMg-Supplementation during HAART Therapy
HAART 治疗期间补充镁的心脏保护作用
  • 批准号:
    8070168
  • 财政年份:
    2010
  • 资助金额:
    $ 23.78万
  • 项目类别:
Protective Efficacy of Mg-Supplementation Against NRTI-induced Cardiac Toxicity
补充镁对 NRTI 诱导的心脏毒性的保护作用
  • 批准号:
    7296101
  • 财政年份:
    2006
  • 资助金额:
    $ 23.78万
  • 项目类别:
Protective Efficacy of Mg-Supplementation Against NRTI-induced Cardiac Toxicity
补充镁对 NRTI 诱导的心脏毒性的保护作用
  • 批准号:
    7229233
  • 财政年份:
    2006
  • 资助金额:
    $ 23.78万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了